Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
MEDICINOVA INC (MNOV)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.45+2.11%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for MNOV yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Stable management and execution of financing agreements | It has stable management and no recent market stress. | Under Pressure | loss of key management or failure to secure financing | SEPA terminated vs maintain equity agreements Company terminated Standby Equity Purchase Agreement with Yorkville on Aug 31, 2026. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making clinical-development business with an optionality-driven thesis, meaning its longer-term case depends on future progress that is not yet reflected in substantial revenue. The thesis is currently intact, with recent financial performance in the top half of its industry, but earnings quality remains fragile.
The valuation model indicates MNOV trades at a premium to peers, while the expectations gap suggests market expectations and fundamentals are not well aligned. Model confidence is low, and the evidence flags the valuation as expensive with weak execution quality, so the premium appears difficult to justify from current results alone.
Near term, revenue has grown from $123,000 in 2025-Q3 to $458,000 in 2026-Q2, and operating losses have narrowed, though revenue remains modest relative to those losses. Management is guiding to an 18% increase in 2026 operating expenses, and the next report carries elevated execution risk, including the possibility of a guidance cut.
The multi-year view depends on continued revenue growth from clinical and development activities alongside further control of operating losses. Near term, a guidance cut or weakening jobs data could weigh on the business context, while continued strong results from healthcare sector leaders could support sector momentum.
MNOV’s long-term thesis has not broken, but the business remains loss-making and its valuation premium rests on progress that is still early. The next test is whether revenue growth and loss reduction continue without a guidance setback. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| MediciNova is advancing its NAFLD drug with a completed phase 2 trial. |
| Under Pressure |
| failure to advance NAFLD drug trials or regulatory setbacks |
Phase 2 mixed data vs Phase 3 target Stock tumbled on mixed Phase 2 NAFLD trial data; Phase 2 visits completed in June 2026. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue reaches at least $16.2 million in 2026 | A primary condition in MEDICINOVA INC's published investment case. The stated target is >=16.2 USD millions. | Intact | revenue falls below $16 million in FY26 | Revenue: $458,439 FY2026-Q2; GAAP. Published target: >=16.2 USD millions. Annual target cannot be compared with a quarterly or TTM observation. Aug 13, 2026458,439 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.38 → $-0.45 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.38 | $800,000 | 1 / 1 |
| 2026-07-25 | $-0.38 | $800,000 | 1 / 1 |
| 2026-07-26 | $-0.38 | $800,000 | 1 / 1 |
| 2026-07-27 | $-0.38 | $800,000 | 1 / 1 |
| 2026-07-28 | $-0.38 | $800,000 | 1 / 1 |
| 2026-07-29 | $-0.38 | $800,000 | 1 / 1 |
| 2026-07-30 | $-0.43 | $400,000 | 1 / 2 |
| 2026-07-31 | $-0.43 | $400,000 | 1 / 2 |
| 2026-08-01 | $-0.38 | $800,000 | 1 / 1 |
| 2026-08-02 | $-0.43 | $400,000 | 1 / 2 |
| 2026-08-03 | $-0.43 | $400,000 | 1 / 2 |
| 2026-08-04 | $-0.43 | $400,000 | 1 / 2 |
| 2026-08-05 | $-0.38 | $800,000 | 1 / 1 |
| 2026-08-06 | $-0.38 | $800,000 | 1 / 1 |
| 2026-08-07 | $-0.38 | $800,000 | 1 / 1 |
| 2026-08-08 | $-0.43 | $400,000 | 1 / 2 |
| 2026-08-09 | $-0.43 | $400,000 | 1 / 2 |
| 2026-08-10 | $-0.38 | $800,000 | 1 / 1 |
| 2026-08-12 | $-0.43 | $400,000 | 1 / 2 |
| 2026-08-13 | $-0.43 | $400,000 | 1 / 2 |
| 2026-08-14 | $-0.38 | $800,000 | 1 / 1 |
| 2026-08-15 | $-0.38 | $800,000 | 1 / 1 |
| 2026-08-16 | $-0.38 | $800,000 | 1 / 1 |
| 2026-08-17 | $-0.38 | $800,000 | 1 / 1 |
| 2026-08-18 | $-0.38 | $800,000 | 1 / 1 |
| 2026-08-19 | $-0.38 | $800,000 | 1 / 1 |
| 2026-08-20 | $-0.38 | $1,000,000 | 1 / 1 |
| 2026-08-21 | $-0.38 | $1,000,000 | 1 / 1 |
| 2026-08-22 | $-0.38 | $1,000,000 | 1 / 1 |
| 2026-08-23 | $-0.38 | $1,000,000 | 1 / 1 |
| 2026-08-24 | $-0.38 | $1,000,000 | 1 / 1 |
| 2026-08-25 | $-0.38 | $1,000,000 | 1 / 1 |
| 2026-08-26 | $-0.38 | $1,000,000 | 1 / 1 |
| 2026-08-27 | $-0.38 | $1,000,000 | 1 / 1 |
| 2026-08-28 | $-0.38 | $1,000,000 | 1 / 1 |
| 2026-08-29 | $-0.38 | $1,000,000 | 1 / 1 |
| 2026-08-30 | $-0.38 | $1,000,000 | 1 / 1 |
| 2026-08-31 | $-0.38 | $1,000,000 | 1 / 1 |
| 2026-09-01 | $-0.38 | $1,000,000 | 1 / 1 |
| 2026-09-02 | $-0.38 | $1,000,000 | 1 / 1 |
| 2026-09-03 | $-0.38 | $1,000,000 | 1 / 1 |
| 2026-09-04 | $-0.38 | $1,000,000 | 1 / 1 |
| 2026-09-05 | $-0.38 | $1,000,000 | 1 / 1 |
| 2026-09-06 | $-0.38 | $1,000,000 | 1 / 1 |
| 2026-09-07 | $-0.38 | $1,000,000 | 1 / 1 |
| 2026-09-08 | $-0.38 | $1,000,000 | 1 / 1 |
| 2026-09-09 | $-0.38 | $1,000,000 | 1 / 1 |
| 2026-09-10 | $-0.38 | $1,000,000 | 1 / 1 |
| 2026-09-11 | $-0.38 | $1,000,000 | 1 / 1 |
| 2026-09-12 | $-0.38 | $1,000,000 | 1 / 1 |
| 2026-09-13 | $-0.38 | $1,000,000 | 1 / 1 |
| 2026-09-14 | $-0.38 | $1,000,000 | 1 / 1 |
| 2026-09-15 | $-0.38 | $1,000,000 | 1 / 1 |
| 2026-09-16 | $-0.38 | $1,000,000 | 1 / 1 |
| 2026-09-17 | $-0.38 | $1,000,000 | 1 / 1 |
| 2026-09-18 | $-0.38 | $1,000,000 | 1 / 1 |
| 2026-09-19 | $-0.45 | $500,000 | 2 / 2 |
| 2026-09-20 | $-0.45 | $500,000 | 2 / 2 |
| 2026-09-21 | $-0.45 | $500,000 | 2 / 2 |
| 2026-09-22 | $-0.45 | $500,000 | 2 / 2 |
| 2026-09-23 | $-0.45 | $500,000 | 2 / 2 |
| 2026-09-24 | $-0.45 | $500,000 | 2 / 2 |
| 2026-09-25 | $-0.45 | $500,000 | 2 / 2 |
| 2026-09-26 | $-0.45 | $500,000 | 2 / 2 |
| 2026-09-27 | $-0.45 | $500,000 | 2 / 2 |
| 2026-09-28 | $-0.45 | $500,000 | 2 / 2 |
| 2026-09-29 | $-0.45 | $500,000 | 2 / 2 |
| 2026-09-30 | $-0.45 | $500,000 | 2 / 2 |
| 2026-10-01 | $-0.45 | $500,000 | 2 / 2 |
| 2026-10-02 | $-0.45 | $500,000 | 2 / 2 |
| 2026-10-03 | $-0.45 | $500,000 | 2 / 2 |
| 2026-10-04 | $-0.45 | $500,000 | 2 / 2 |
| 2026-10-05 | $-0.45 | $500,000 | 2 / 2 |
| 2026-10-06 | $-0.45 | $500,000 | 2 / 2 |
| 2026-10-07 | $-0.45 | $500,000 | 2 / 2 |
| 2026-10-08 | $-0.45 | $500,000 | 2 / 2 |
| 2026-10-09 | $-0.45 | $500,000 | 2 / 2 |
| 2026-10-10 | $-0.45 | $500,000 | 2 / 2 |
| 2026-10-11 | $-0.45 | $500,000 | 2 / 2 |
| 2026-10-12 | $-0.45 | $500,000 | 2 / 2 |
| 2026-10-13 | $-0.45 | $500,000 | 2 / 2 |
| 2026-10-14 | $-0.45 | $500,000 | 2 / 2 |
| 2026-10-15 | $-0.45 | $500,000 | 2 / 2 |
| 2026-10-16 | $-0.45 | $500,000 | 2 / 2 |
| 2026-10-17 | $-0.45 | $500,000 | 2 / 2 |
| 2026-10-18 | $-0.45 | $500,000 | 2 / 2 |
| 2026-10-19 | $-0.45 | $500,000 | 2 / 2 |
| 2026-10-20 | $-0.45 | $500,000 | 2 / 2 |
| 2026-10-21 | $-0.45 | $500,000 | 2 / 2 |
| 2026-10-22 | $-0.45 | $500,000 | 2 / 2 |
| 2026-10-23 | $-0.45 | $500,000 | 2 / 2 |
| 2026-10-24 | $-0.45 | $500,000 | 2 / 2 |
| 2026-10-25 | $-0.45 | $500,000 | 2 / 2 |
| 2026-10-26 | $-0.45 | $500,000 | 2 / 2 |
| 2026-10-27 | $-0.45 | $500,000 | 2 / 2 |
| 2026-10-28 | $-0.45 | $500,000 | 2 / 2 |
| 2026-10-29 | $-0.45 | $500,000 | 2 / 2 |
| 2026-10-30 | $-0.45 | $500,000 | 2 / 2 |
| 2026-10-31 | $-0.45 | $500,000 | 2 / 2 |
| 2026-11-01 | $-0.45 | $500,000 | 2 / 2 |
| 2026-11-02 | $-0.45 | $500,000 | 2 / 2 |
| 2026-11-03 | $-0.45 | $500,000 | 2 / 2 |
| 2026-11-04 | $-0.45 | $500,000 | 2 / 2 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 4 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.